BV2 (小鼠小胶质细胞)(STR鉴定)
BV-2细胞是由E·Blasi建立于1990年;BV-2细胞由小鼠小神经胶质细胞经逆转录病毒介导转染v-raf/v-myc获永生化。BV-2细胞保留有小神经胶质细胞多种形态、表征和功能特征;免疫组化结果显示,BV-2细胞为MAC1、MAC2阳性;而MAC3、胶质细胞原纤维酸性蛋白、半乳糖脑苷脂为阴性。
01产品图片

02产品简介
BV-2细胞是由E·Blasi建立于1990年;BV-2细胞由小鼠小神经胶质细胞经逆转录病毒介导转染v-raf/v-myc获永生化。BV-2细胞保留有小神经胶质细胞多种形态、表征和功能特征;免疫组化结果显示,BV-2细胞为MAC1、MAC2阳性;而MAC3、胶质细胞原纤维酸性蛋白、半乳糖脑苷脂为阴性。
03产品介绍
BV-2细胞是由E·Blasi建立于1990年;BV-2细胞由小鼠小神经胶质细胞经逆转录病毒介导转染v-raf/v-myc获永生化。BV-2细胞保留有小神经胶质细胞多种形态、表征和功能特征;免疫组化结果显示,BV-2细胞为MAC1、MAC2阳性;而MAC3、胶质细胞原纤维酸性蛋白、半乳糖脑苷脂为阴性。
1) 来源:C57BL/6小鼠,脑,胶质瘤
2) 形态:上皮细胞样,松散贴壁,悬浮和贴壁细胞混合生长
4) 培养条件: MEM+10%FBS+ 1%P/S (推荐货号AW-MC003)
1) 收到细胞后,活细胞首先观察培养瓶是否完好,培养液是否漏液,培养基是否浑浊;冻存细胞是否干冰已挥发完,冻存管盖是否脱落,破碎,若有这类情况,请务必拍照记录,并于收货24h内与我们联系。
复苏的细胞:如果是T-25培养瓶活细胞,收到后请用75%的酒精对培养瓶表面进行消毒处理,然后转入培养箱中静置2~3h后再进行后续处理。
备注:运输用的培养基不宜再次用来培养细胞,请按照 新配置完全培养基来培养细胞。
冻存细胞:如果是干冰运输的冻存细胞,收到后请立即转入液氮存储或者短暂(24h)放置-80度冰箱保存,或者直接进行细胞复苏。
认真做好每一个抗体, 每一个抗体都经过反复验证!
空气,95%;二氧化碳,5%
细胞复苏、传代及冻存流程参考
1) 配制完全培养基:基础培养基+胎牛血清+双抗(特殊培养基特殊配置)
2) 细胞复苏:取5ml完全培养基于15ml离心管中,37℃水浴锅预热,从液氮管(或者-80度冰箱)中快速取出冻存的细胞,放入37℃水浴锅中,摇晃使快速化冻(1min左右),然后将化冻的细胞和预热的培养基,移入超净工作台中,化冻的细胞加入到含预热培养基的15ml离心管中,1000rpm离心5min
3) 吸弃上清,得到细胞沉淀,用2ml完全培养基轻轻重悬细胞,加入到T25培养瓶中,做好标记,放入37℃,5%CO2饱和适度培养箱中培养(培养皿复苏效果更好)
4) 24h后,观察细胞贴壁情况(未贴壁的即为死细胞--针对贴壁细胞),吸弃旧培养基,加入新鲜的预热(室温或37℃)的完全培养基,继续培养。
1) 待细胞生长到80%-90%汇合度时,吸弃旧的培养基,加入1ml无菌PBS润洗一次,以去除残余的培养基及血清(血清含有胰酶的抑制因子),然后加入1ml 0.25%胰酶,37℃培养箱中消化(1~2min左右,不同细胞消化时间不同),取出细胞,镜下观察细胞至细胞皱缩变圆
2) 加入1ml完全培养基(含FBS)终止消化,轻轻拍打,使细胞脱落下来成单个细胞悬液,收集细胞于15ml无菌离心管中,1000rpm,离心5min
3) 收集细胞沉淀,完全培养基重悬,一分为二(可根据细胞生长速度调整比例),分别加入到2个新的培养瓶中,做好标记,放入培养箱中培养。
1) 按照细胞传代方法,在超净工作台内消化收集细胞沉淀,取少量细胞用于计数
2) 用预冷的1ml冻存液(90%完全培养基+10%DMSO)或者无血清细胞冻存液重悬细胞,加入到1.2ml冻存管中,密度为1*106个/ml。
3) 放入程序冻存盒,-80℃过夜后,转入液氮长期保存。
Normal tension glaucoma (NTG) is a predominant subset of glaucoma in Asia and is characterized by glaucomatous optic neuropathy in the absence of elevated intraocular pressure. Alterations in retinal blood vessels are reported to be important mechanisms of glaucomatous optic nerve damage. Retinal peripapillary vascular density is assessed in patients with early stage NTG and OPTN (E50K) mutant mice and confirmed a similar reduction in retinal peripapillary vascular density in patients with NTG and model mice. Thus, identifying the mechanisms underlying retinal vascular changes in NTG is crucial for developing effective therapeutic strategies. This study revealed that Rpl17 is upregulated in the retinal microglia of OPTN (E50K) mutant mice. Rpl17 exerts regulatory control over Apoa1 by directly interacting with Stat5b, which causes damage to retinal vascular endothelial cells and leads to a reduction in retinal peripapillary vascular density. Additionally, we identified ellagic acid (EA) as an Apoa1 antagonist that is able to alleviate damage to retinal vascular endothelial cells and increase retinal peripapillary vascular density, which subsequently protected retinal ganglion cells and improved visual function. The work elucidates the vascular mechanism of NTG optic nerve damage and proposes EA as an effective adjuvant therapy strategy.
Authors:Di Zhang, Sisi Chen, Yanfeng Zhang, Leyi Qiu, Mengxian Du, Wulian Song, Fengyi Guo, Jingyang Zhang, Xinna Liu, Huiping Yuan Authors:Wang Shuling, Hu Yujie, Xu Sizhe, Yang Guoshuai
Normal-tension glaucoma (NTG) is a subtype of primary open-angle glaucoma (POAG). Patients with NTG still experience significant optic nerve damage despite maintaining normal intraocular pressures. The mechanism of optic nerve damage in glaucoma with normal pressure is still unclear. Research has shown that OPTN (E50K) mutations exacerbate the inflammatory response of retinal microglia. However, there is still a lack of evidence on how OPTN (E50K) mutations directly regulate their inflammatory pathways through key molecules. This study explores the role of microglial inflammation caused by the interaction between IRF7 and NLRP3 molecules in NTG optic nerve injury. Single-cell RNA sequencing (scRNA-seq) was employed to analyze retinal microglial cells from both wild-type (WT) and OPTN (E50K) mutant mice. The analysis revealed significant enrichment of inflammatory pathways and a critical role of IRF7 in modulating NLRP3 activation. Techniques such as Western blot (WB), qPCR, immunofluorescence (IF), and molecular docking were utilized to confirm the interactions between IRF7 and NLRP3. The findings demonstrate that the OPTN (E50K) mutation reduces the suppressive effect of IRF7 on NLRP3, leading to a pro-inflammatory microglial phenotype and exacerbating the optic nerve damage of NTG. This study provides a new therapeutic target for the treatment of NTG optic nerve damage.
Authors:Leyi Qiu, Fengyi Guo, Xinna Liu, Di Zhang, Qi Wang, Mengxian Du, Qianmei Yuan, Shiqi Zhang, Wulian Song, Huiping Yuan
In recent years, the application of engineered NMts has significantly contributed to various biomedical fields. ZnO NMts (ZnO NMts) are widely utilized due to their biocompatibility, unique physical and chemical properties, stability, and cost-effectiveness for large-scale production. They have emerged as potential materials for anti-cancer applications. This study aims to study the impact of ZnO Nanorod flowers (ZnO NRfs) and their combination with temozolomide (TMZ) on glioma cells. Normal mouse microglia (BV2) will be used as a control to assess the effects on mouse glioma cells (G422) and human glioma cells (LN229). The effects of these substances were evaluated on G422 and LN229 cells through various parameters such as IC50 value, Zn2+ accumulation, ROS production, apoptosis, mitochondrial membrane potential (MMP) depolarization, and examination of organelles like mitochondria and lysosomes. Additionally, hypoxia-inducible factor-1α (HIF-1α), endothelial cell PAS domain protein 1 (EPAS1), autophagy markers (LC3), mitophagy and phagocytosis marker (BNIP3) were assessed. The results demonstrated that the combination of ZnO NRfs and TMZ could influence the expression of HIF-1α, EPAS1, LC3, and BNIP3 proteins, leading to mitophagy in glioma cells. This combination treatment has the potential to effectively eliminate glioma cells by activating the mitophagy pathway, which provides a good prospect for the clinical treatment of glioma.
Authors:Yuanyuan Li, Yonghua Ma, Jingjing Li, Yan Lu, Haiying Liu, Min Gao, Junqin Cao International Journal of Nanomedicine IF:6.6 Authors:Qi Wang, Jiaxin Dong, Mengxian Du, Xinna Liu, Shiqi Zhang, Di Zhang, Wanyun Qin, Xikun Xu, Xianghui Li, Ruidong Su, Leyi Qiu, Baoqiang Li, Huiping Yuan JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY IF:6.2
Microbiota dysfunction induces intestinal disorders and neurological diseases. Mannuronate oligosaccharides (MAOS), a kind of alginate oligosaccharide (AOS), specifically exert efficacy in shaping gut microbiota and relieving cognitive impairment. However, the key regulatory factors involved, such as the specific strains and metabolites as well as their regulatory mechanisms, remain unclear at present. This research investigates how MAOS specifically impact the gut–brain axis in vivo and in vitro. The results showed that pretreatment with MAOS significantly ameliorated dextran sodium sulfate (DSS)-induced colitis and secondary nerve injury. This preventive mechanism operates through the regulation of serum DOPC abundance and the gut–brain axis, achieved by inhibiting the TLR4/MyD88/NF-κB pathway. These findings underscore the crucial role of dietary MAOS in the prevention of colitis and neurological disorders, providing a rationale for the application of MAOS in disease prevention and functional food ingredients.
Authors:Shuang Lu, Zhengxiong Tao, Gan Wang, Kai Na, Lisha Wu, Li Zhang, Xiangyu Li, Xiaohua Guo Authors:Ma Ya-nan, Wang Zijie, Liang Yuchang, Tan Guoao, Hu Xiqi, Xia Ying Authors:Mengqin Yuan, Jinda Hu, Lichen Gao, Wei Long, Sirui Wang, Xinyue Tan, Jinyue Hu Authors:Ling Zhu, Congyan Liu, Yang Wang, Xuanang Zhu, Lei Wu, Lvan Chen, Jing Zhou, Fan Wang 细胞描述: GH3细胞系是由Tashjian AH等在1965年7月从一只7月龄的雌性Wistar-Furth大鼠的垂体肿瘤中分离建立的。GH3细胞系不是直接来源于GH1细胞系的克隆,而是从原代培养的GH1细胞在大鼠身上传代两次形成的肿瘤中建立的。上皮样的GH3细胞比GH1分泌更高水平的生长激素,也可产生
细胞描述: 胶质细胞株C6是由Benda等用N-nitrosomethylurea诱导的大鼠胶质瘤克隆,并经过一系列的体外培养和动物传代交替后建成的。当细胞从低密度生长到满瓶时,S-100产量增加10倍。 细胞特性: 1)来源:大鼠,胶质瘤 2)形态:成纤维细胞样,贴壁生长 3) 6 cells 细胞描述: 克隆Neuro-2A是由R·J·Klebe和F·H·Ruddle经A株白鼠的自生肿瘤建立。该细胞产生大量微管蛋白,此蛋白在神经细胞中起应答轴浆流动的收缩系统作用。 细胞特性: 1)来源:脑神经母细胞瘤 2)形态:阿米巴样干细胞,贴壁生长 3) 6 cells 4)培养条件: MEM+ 细胞描述: 此AML12(α小鼠肝脏12)细胞系由来自针对人TGFα的转基因小鼠(CD1菌株,品系MT42)的肝细胞建立。通过电子显微镜观察,这些细胞表现出典型的肝细胞特征,例如过氧化物酶体和胆小管样结构。AML12细胞保留表达血清(白蛋白,α1抗胰蛋白酶和转铁蛋白)和间隙连细胞描述: OVCAR-3细胞由T·C·Hamilton在1982年建系。取于患进行性卵巢腺癌病人的恶性腹水。NIH-OVCAR-3是研究卵巢癌药物抗性的一个合适的模型系统且由于存在激素受体,这对于激素治疗的评估或许是有用的。 细胞特性: 1)来源: 卵巢 2)形态:上皮细胞样,贴壁生长 3)规格
细胞描述: 该细胞是从一名13岁的白人女性的骨肉瘤组织中分离建立的,表现为扁平形态、低饱和密度、软琼脂中的低克隆形成率和对化合物及病毒感染的敏感性。 细胞特性: 1)来源:骨 2)形态:上皮细胞样,贴壁生长 3) 6 cells 4)培养条件: MEM+10%FBS+1%NEAA+1 细胞描述: 该细胞系于1982年建立,从一位56岁白种男性的病变舌中间部分取得,该细胞具高密度颗粒状胞浆。 细胞特性: 1)来源:舌 2)形态:上皮细胞样,贴壁生长 3) 6 cells 4)培养条件: DMEM+10%FBS+1%P/S 空气,95%;二氧化碳,5% 37℃ 细胞接收后的处理: 1)收细胞描述: HEK-293T细胞是293T(293tsA1609neo)细胞系(ATCC CRL-11268)的衍生物。细胞持续表达SV40抗原,该细胞常用于转染实验,转染效率较高。(转染一般以50%密度铺板,待细胞刚刚贴到皿壁上后(一般8-10小时),即可进行转染操作)。 细胞特性: 1)来源: 人胚胎肾脏 2)形这株细胞于1988年七月建株,组织提供者是一位非吸烟人士。
该人胰腺癌细胞PANC-1来源于一名56岁白人男性。1 U/ml 左旋天冬酰胺酶(L-asparaginase)可抑制其生长。此细胞可以在琼脂糖上生长。其倍增时间为52小时,G6PD活性处于低泳动性的B型。染色体研究表明模式数目为63,包括3个独特标记的染色体和1个小环状染色体。 以下二点证明它的恶性:(1)在软琼脂上和单层成纤维细胞上的快速生长,(2)注入无胸腺裸鼠后形成日益增长的成长型未分化癌。
相关资料下载:说明书(.pdf)(点击从官网下载)
04完整参数表
参数由厂商资料整理,采购前请以最终报价单与技术协议为准。
05荣誉与资质
该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。
- 营业执照未上传
- 品牌授权未上传
- 产品检测报告未上传
- 会员身份
- 收费会员
- 经营身份
- 原厂
- 成立年份
- 2016 年
- 所在地
- 湖南
- 收录条目
- 498 个
- 平台核验
- 平台代管
06品牌与供应商
公司产品涵盖抗体、细胞、培养基、质粒载体等多个领域,致力于为生命科学研究提供可靠的工具与解决方案。自创立以来,艾碧维始终秉持“求实、诚挚、勤勉、克己”的发展理念,坚持以自主研发与持续创新为核心动力。公司拥有百余人的团队,其中硕士及以上学历生物医学专业人才占比超过30%,包括博士4人,构建起一支结构合理、专业扎实的研发与服务队伍。通过设立研发部、生产部、市场与营销部、财务部等多功能部门,公司实现了从产品开发到市场推广的全流程管控。艾碧维不仅敢于质疑现状,积极为生命科学家突破技术壁垒提供支撑,更注重与客户的深度互动与合作,通过持续收集反馈、开展研发协作,提前预见并解决潜在问题。未来,公司将继续秉持“助力科研创新,让实验更简单”的使命,一步一个脚印地打造具有国际领先水平的技术研发与产业化平台,为全球生命科学领域的进步持续赋能。注意: 1.本公司产品仅供科研使用。
品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。
07同类条目
同一子类内的条目才具备可比性。跨子类比较参数通常没有意义。
08同品牌其他条目
艾碧维 在本目录共 498 个条目,除本条外还有:
科研在线(TeleVM). BV2 (小鼠小胶质细胞)(STR鉴定)(AW-CNM081)[EB/OL]. 产品目录, 2026-10-31. https://www.suprotek.cn/products/item/aw-cnm081.html.
TeleVM. (2026, October 31). BV2 (小鼠小胶质细胞)(STR鉴定)(AW-CNM081). 产品目录. https://www.suprotek.cn/products/item/aw-cnm081.html
@misc{biocsp_item_aw_cnm081,
title = {BV2 (小鼠小胶质细胞)(STR鉴定)(AW-CNM081)},
author = {{科研在线}},
year = {2026},
howpublished = {产品目录},
note = {更新于 2026-10-31,产品目录},
url = {https://www.suprotek.cn/products/item/aw-cnm081.html}
}
GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。
许可:CC BY-NC 4.0 · 转载注明来源